Schering-Plough has begun the enrolment process for a study focused on acadesine.
Acadesine is being investigated as a possible treatment via intravenous infusion to prevent ischemia-reperfusion injury. This is a complication sometimes experienced by people undergoing coronary artery bypass graft surgery with a cardiopulmonary bypass procedure.
The company said it has started to recruit subjects for the phase III RED-CABG trial, after having licensed the drug from privately-held pharmaceutical company PeriCor Therapeutics.
Complication rates from the aforementioned operations are "unacceptably high", it added.
"Schering-Plough is committed to addressing the significant unmet medical need in ischemia-reperfusion injury in this patient population," remarked Dr Enrico Veltri, group vice-president of global clinical research, cardiovascular and metabolic diseases at the Schering-Plough Research Institute.
Meanwhile, the end of last month saw the company release final results from its three large Pegintron (peginterferon alfa-2b) clinical studies for the treatment of hepatitis C.
They were presented at the 44th European Association for the Study of the Liver.See all the latest jobs in Pharmaceutical